Merck Reports FDA Approved KEYTRUDA In Combo With Carboplatin, Either Paclitaxel Or Nab-Paclitaxel For First-Line Treatment Of Patients With Metastatic Squamous Non-Small Cell Lung Cancer
Benzinga Newsdesk